newsfilter
← Earnings
Earnings Releases·

Collegium Pharmaceutical — Q3 2026 Earnings Summary

Collegium Pharmaceutical reported record quarterly net revenues of $216.3 million for the third quarter of 2026, representing a 3% increase year-over-year. The company's ADHD portfolio drove significant growth, with JORNAY PM revenues rising 24% to $51.9 million and AZSTARYS generating $26.5 million in its first full quarter under Collegium's ownership. Despite a decline in the pain portfolio, the company achieved adjusted EBITDA of $121.6 million and reaffirmed its full-year 2026 financial guidance. Additionally, Collegium announced a $50 million accelerated share repurchase program expected to settle by the end of the year.

Company
COLLEGIUM PHARMACEUTICAL INC
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic